Opioid Litigation Proceeds: Summary of State Laws
In this document, the Legislative Analysis and Public Policy Association (LAPPA) examines the state-level legislative response to opioid manufacturer and distributor litigation....
In this document, the Legislative Analysis and Public Policy Association (LAPPA) examines the state-level legislative response to opioid manufacturer and distributor litigation....
The purpose of the Model Building the Substance Use Disorder Workforce of the Future Act is to address the current and projected shortage of professions for the substance use disorder workforce, including psychiatrists, psychologists, physicians who are certified in addiction medicine, addiction counselors, social workers, nursing professionals, peer support professionals, and others. This legislation guides states in adopting a strategy that supports and advances immediate, intermediate, and long-term measures to build and sustain an SUD workforce....
In the fall of 2022, West Virginia implemented an opioid and substance misuse prevention program named Game Changer in three public high schools. The first of its kind in the nation program uses student peer leadership programs that focus on building school environments that foster and promote healthy living and staying away from using or experimenting with alcohol and drugs....
To complement the opioid prescribing guidelines that the University of Buffalo Department of Emergency Medicine established in 2016, Dr. Joshua Lynch developed the Medication for Addiction Treatment and Electronic Referrals (MATTERS) program. He saw the need for MATTERs because the “window of opportunity” to help someone with a substance use disorder is small, and he wanted to immediately link a patient who had overdosed to a treatment program that is right for that individual....
The key elements of the Model Overdose Reversal Agents Act are to: (1) remove all existing restrictions about who can receive, possess, store, transfer without cost, or administer an ORA such that any “person or entity” is eligible; (2) require specified individuals and entities to offer ORAs to individuals at increased risk of overdose; (3) require emergency access to ORAs at specified locations for use by any individual; (4) provide guidelines for ORA sales, in particular sales of non-prescription ORAs; (6) grant broad immunity to people or entities for prescribing, dispensing, giving, donating, transferring without charge, selling, or administering ORAs in the absence of gross negligence, malice, or criminal intent; (7) identify the required content for educational information about ORAs and specify when that information must be disseminated; (8) require Medicaid and other health insurance coverage for ORAs, including non-prescription ORAs, and prohibit discriminatory life and health insurance practices; and (9) create a bulk overdose reversal agent purchasing fund to assist persons and entities to fulfill requirements under the Act....
In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) discusses the emergence of "tusi," which is also known as pink cocaine. Tusi is a group of psychedelic drugs common amongst clubgoers, dyed pink, that actually rarely contains cocaine. While tusi itself is not controlled under the Controlled Substances Act, its individual components like ketamine and fentanyl often are, and because users rarely know what is in the particular mix they are ingesting, they cannot anticipate the side effects....
In 2018, the city of Chicago, IL gained an ally in the fight against fatal overdoses and substance use disorder in the non-profit organization, To Walk in My Shoes. Co-founded by Marnell Brown, a person in long term recovery, To Walk in My Shoes provides resources and support for those in need in the community. In addition to providing individuals with job skills training, including interview practice and how to write a resume, money management skills, and conflict resolution skills, To Walk in My Shoes also works to raise awareness about and provide testing for HIV/AIDS....
The Legislative Analysis and Public Policy Association (LAPPA), in partnership with the Institute for Intergovernmental Relations, developed several resources related to overdose fatality review (OFR), including a complete summary of state OFR laws, a guide on how OFR teams can obtain information from the Indian Health Service, and a guide on how OFR teams can obtain information from the Veterans Health Administration....
In this document, the Legislative Analysis and Public Policy Association (LAPPA) determines how health insurance statutes throughout the 50 states, District of Columbia, and all U.S. territories treat mental health and SUD parity....
In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) details the changes to the "primary diagnosis other than OUD" regulation. The fact sheet also covers the federal regulatory scheme for methadone for OUD and explains what led SAMHSA to revise its regulations. ...